Complement Therapeutics

Complement Therapeutics is a preclinical-stage biotechnology company focused on developing novel therapeutics for complement-mediated diseases, with a primary focus on ophthalmology. The company's lead program, CTx001, is an AAV-based gene therapy designed to treat geographic atrophy secondary to age-related macular degeneration by delivering a functional copy of the complement factor I gene. Utilizing its proprietary CTx Discovery Platform, the company identifies and validates new targets to address unmet needs in various complement-driven pathologies. A spin-out from the University of Manchester, the company operates across Germany and the United Kingdom to advance its pipeline of innovative genetic medicines.